REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating Results FDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in the

Zoom Virtual Agent expands to Zoom Phone, enabling a new concierge use case that delivers personalized support with agentic concierge capabilities to automate routine calls and streamline frontline service across departments Zoom AI Companion enhances agentic scheduling to coordinate meetings end-to-end, finding the best time, contacting attendees, tracking responses, and recommending next steps without the back-and-forth Zoom Hub launches, providing a centralized workspace to create, find, and manage Zoom files Zoom Team Chat adds AI Companion to mobile for easier catch-up, and quick document summaries without needing to open the file in the Zoom Workplace desktop app, saving time and

Extrovis AG Bahnhof Park 4 6340, Baar, Switzerland Media Relations Contact Madhu Marur [email protected] Press Release Extrovis AG and Dr. Reddy’s announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the

Lantronix Enables TAA- and NDAA-Compliant Edge AI Solution, Supporting Sensitive U.S. Government Missions and Expanding Long-Term Defense Market Positioning IRVINE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, today announced that its TAA- and NDAA-compliant solution was selected by Teal Drones, a Red Cat Holdings Inc. (NASDAQ: RCAT) company, for production of its Black Widow drones under the U.S. Army’s Short-Range Reconnaissance (SRR) Program. Lantronix has already initiated production shipments, providing early revenue visibility and underscoring Lantronix’s role as a trusted technology partner for

Offers shareholders an additional $0.35 per share Ethereum Loyalty Payment for moving shares to Book Entry SILVER SPRING, MD, Aug. 18, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced that it is paying shareholders a one-time blockchain dividend, or “Bividend” of $0.05 per share in Ethereum (ETH). The Bividend marks the first time a public company has paid a dividend in ETH. BTCS is also offering a one-time $0.35 per share loyalty payment, payable solely in ETH, to shareholders who move their shares to

Offers shareholders an additional $0.35 per share Ethereum Loyalty Payment for moving shares to Book Entry SILVER SPRING, MD, Aug. 18, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced that it is paying shareholders a one-time blockchain dividend, or “Bividend” of $0.05 per share in Ethereum (ETH). The Bividend marks the first time a public company has paid a dividend in ETH. BTCS is also offering a one-time $0.35 per share loyalty payment, payable solely in ETH, to shareholders who move their shares to

Offers shareholders an additional $0.35 per share Ethereum Loyalty Payment for moving shares to Book Entry SILVER SPRING, MD, Aug. 18, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced that it is paying shareholders a one-time blockchain dividend, or “Bividend” of $0.05 per share in Ethereum (ETH). The Bividend marks the first time a public company has paid a dividend in ETH. BTCS is also offering a one-time $0.35 per share loyalty payment, payable solely in ETH, to shareholders who move their shares to